Acute Lymphoblastic Leukemia

Overview

Oncology fellows and pediatric oncology fellows who are nominated to attend the Acute Lymphoblastic Leukemia Fellows Scholar Program (ALLFSP) are selected by their program directors. Ideal candidates for the program are dedicated to enhancing their understanding of acute lymphoblastic leukemia (ALL) across various age groups and to advancing their knowledge of treatment methods. During this multi-day meeting, fellows attend interactive learning sessions with expert faculty and participate in breakout workshops in which they discuss clinical cases with colleagues from across the United States. Each participant is required to prepare and present one brief case study on an ALL-related topic of their choice.

Activity Description

The ALLFSP is an intensive multi-day course designed for adult and pediatric hematology/oncology fellows to expand their education and understanding of the complex and evolving therapeutic space of ALL. The primary objective for the third installment of this program is to provide fellows with a thorough review of the current management for ALL across diverse patient populations. Additionally, the agenda aims to foster discussions on evaluating and differentiating current treatment options, refining treatment approaches and care plans, the future trajectory of therapy, and the questions that are driving research.

Who Should Attend

Fellows who are nominated to attend the ALLFSP are selected by their program directors. Ideal candidates for the program are at least in their second year of an adult or pediatric hematology/oncology fellowship (exceptions for first-year fellows may be considered on a case-by-case basis) and are committed to furthering their knowledge of the treatment of ALL. During this multi-day meeting, fellows attend interactive learning sessions with expert faculty and participate in breakout workshops in which they discuss clinical cases with colleagues from across the United States. Each registrant is required to prepare and present one brief case study on an ALL-related topic of their choice. Attendees of the 2026 ALLFSP will receive a detailed electronic handout and other resources related to the treatment of ALL.

Travel

Each participant will receive a $450 travel scholarship on-site at ALLFSP.

• Attendees are responsible for their airfare to and from Chicago.
• Attendees will reserve a hotel room via a secure hotel website once registration is confirmed.

*Travel scholarships are available for all learners, supported by CEC.

Case Study

All registrants are required to present an ALL-related clinical case during their assigned case study breakout session. All case study presentations must be submitted in advance in PowerPoint format. The presentation should include no more than 6–8 slides, with the expectation of approximately 10 minutes for both presentation and discussion. Case study submission requirements will be emailed to fellows following registration.

Learning Objectives

1. Select age‑appropriate, risk‑adapted frontline regimens for pediatric, AYA, and adults with ALL.
2. Select appropriate therapies for relapsed/refractory (R/R) ALL based on prior treatment exposure and disease risk.
3. Integrate strategies to mitigate and manage acute and chronic toxicities in patients with Ph+ ALL receiving tyrosine kinase inhibitors (TKIs) and immunotherapies.
4. Apply evidence-informed approaches to the management of lineage switch between ALL and acute myeloid leukemia (AML).
5. Align treatment recommendations with patient values and goals in survivorship care for adolescents and young adults with ALL.
6. Incorporate strategies to improve care coordination for patients with ALL in community oncology settings.